|Articles|November 2, 2015

Stories of Life With Esophageal Cancer: Brian and Karen

This video was produced by The Esophageal Cancer Awareness Association. It features the compelling stories of EC survivors: Brian Galgay and Karen Kent.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!

Related Content

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower: © stock.adobe.com.

Fertility Decisions Influenced by Age and Parental Status in Premenopausal Breast Cancer

ByRyan Scott

December 12th 2025

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Inluriyo/Verzenio Extends Treatment Benefit in ER+/HER2– Breast Cancer

ByJason Broderick

December 12th 2025

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

BySpencer Feldman

December 12th 2025

HRT Use Does Not Raise Breast Cancer Risk in BRCA Carriers

ByPaige Britt

December 12th 2025

Electronic Intervention Improves Quality of Life in Younger Breast Cancer Survivors

ByAlex Biese

December 12th 2025

Stories of Life With Esophageal Cancer: Brian and Karen

Newsletter

Related Content

Fertility Decisions Influenced by Age and Parental Status in Premenopausal Breast Cancer

Inluriyo/Verzenio Extends Treatment Benefit in ER+/HER2– Breast Cancer

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

HRT Use Does Not Raise Breast Cancer Risk in BRCA Carriers

Electronic Intervention Improves Quality of Life in Younger Breast Cancer Survivors

Trending on CURE

Acupuncture Improves Cognitive Function in Breast Cancer Survivors

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

Suleika Jaouad, Reporting From the Front Lines of Leukemia

FDA Grants Priority Review for Opdivo Combo in Advanced Lymphoma